ImmuPharma: FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients



ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an update on the announcement issued on 10 November 2020, in respect to the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus (“SLE”), a potentially life-threatening auto-immune disease.

The US Food & Drug Administration (“FDA”) has now confirmed the date of 4 December 2020 for a Type ‘A’ Meeting Request, with Avion Pharmaceuticals (“Avion”), ImmuPharma’s licensing partner for Lupuzor™.

As part of the Type ‘A’ Meeting, Avion has asked the FDA for guidance on the following:

·    Key aspects of the study design, clinical end points and approval process for Lupuzor™; and

·    Consideration by the FDA for a conditional approval of Lupuzor™, whilst the Phase 3 trial is underway.

ImmuPharma will provide an update as soon as Avion has met with the FDA and notified ImmuPharma of the outcome.

Commenting on the announcement, Dimitri Dimitriou, CEO of ImmuPharma said: “ImmuPharma and Avion are delighted that the FDA are expediting the Type ‘A’ Meeting for early December 2020.  We look forward to providing a further update to the market following confirmation from Avion of the FDA’s guidance post this meeting.”




Artikel geplaatst n.a.v. bron:
 
Op:  20-11-2020

Artikel ongepast?

Dit artikel is ongepast

Gelieve ons te laten weten waarom u dit artikel ongepast acht.

Gelieve je eerst aan te melden.
Registreren en berichten schrijven is gratis.


Registreer hier! Aanmelden!
Project: Open ondernemerschap!

Wens je meer visibiliteit, meer leads naar je onderneming of product?
Gebruik dan onze voordelige bedrijfspagina en wordt door duizenden bezoekers online gevonden!





Wil je gratis ondernemersnieuws plaatsen?
 



Meer nieuws over bizz com

Brussel
24-11-2020

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that Lind Global Macro Fund, LP (“Lind”) has converted $355,112.50 (plus accrued but unpaid interest) of the convertible security issued pursuant to the convertible security deed dated 10 June 2020, details of which were announced by the Company on 11 June 2020....


Meer info

bizz com
Brussel
23-11-2020

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has converted $200,000 (plus accrued but unpaid interest) of the convertible security issued pursuant to the convertible security deed dated 10 June 2020, details of which were announced by the Company on...


Meer info

bizz com
Brussel
18-11-2020

Luxemburg, 18 november 2020 – Lombard International Assurance S.A., een vooraanstaande aanbieder van vermogens- en successieplanningoplossingen voor vermogende particulieren, families en instellingen, slaat de handen in elkaar met Capital Group, een van de grootste en meest ervaren beleggingsvennootschappen ter wereld, om zijn Multisupport Tak-23 oplossingen in België verder uit te...


Meer info

bizz com



Advertenties



Klik hier voor het nieuws uit
Maas en Kempenland | Antwerpen | VL-Brabant | Limburg | Kempen | Oost-VL | West-VL | Brussel | De Kust |

Media Partners

X
Geen vervelende pop-up meer?
Geen probleem meld je gewoon aan, de digitale krant is gratis.
Bovendien kan je ook zelf artikels plaatsen.
inVlaanderen.be gebruikt cookies en verzamelt gegevens om de gebruikersnelheid te kunnen verbeteren. Meer info: https://www.invlaanderen.be/pagina/privacy

Ok, ik snap het